Silexion Therapeutics Corp (NASDAQ:SLXN) Sees Significant Growth in Short Interest

Silexion Therapeutics Corp (NASDAQ:SLXN) was the recipient of a large increase in short interest in the month of October. As of October 15th, there was short interest totaling 152,700 shares, an increase of 428.4% from the September 30th total of 28,900 shares. Based on an average daily volume of 498,700 shares, the short-interest ratio is presently 0.3 days. Approximately 6.3% of the shares of the stock are short sold. Approximately 6.3% of the shares of the stock are short sold. Based on an average daily volume of 498,700 shares, the short-interest ratio is presently 0.3 days.

Silexion Therapeutics Price Performance

SLXN stock opened at $3.47 on Tuesday. The firm’s 50-day moving average price is $4.79 and its two-hundred day moving average price is $9.84. Silexion Therapeutics has a 12-month low of $3.25 and a 12-month high of $63.45. The stock has a market capitalization of $10.86 million, a price-to-earnings ratio of -0.01 and a beta of -0.07. The company has a current ratio of 2.44, a quick ratio of 2.44 and a debt-to-equity ratio of 26.58.

Silexion Therapeutics (NASDAQ:SLXN) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($4.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.15) by ($1.17).

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Silexion Therapeutics in a report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $75.00.

About Silexion Therapeutics

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.